RXRXRecursion Pharmaceuticals Inc.Signing up patients
REC-7735 in Participants With Solid Tumors
Solid Tumors
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 90 (planned)
- Started
- Sep 2026
- Main results expected
- Jan 2031
- Fully finished
- Jan 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1A: Number of Participants With Dose-limiting Toxicities (DLTs)
Measured over: 28 days
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Measured over: Up to 2 years
Phase 1B: Objective Response Rate (ORR) According to Standard Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measured over: Up to 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07819136 · record last updated 2026-09-29 · checked 2026-11-09 15:47 UTC